Scribe Therapeutics prices upsized IPO at $15/share
Seeking Alpha ·
Scribe Therapeutics ( SCTX ) priced its upsized IPO of 8.58M shares at $15.00 per share, the top of its marketed range. It is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies ( CRSP )designed to extend healthy lifespan through
DYAX Investor Sentiment
Bullish (Long) 63% · Bearish (Short) 37%
368 participants
Related News
- I Ran the Numbers on Retiring 5 Years Early With VOO. Here's What Changed My Mind.
- SL Green projects $1.20-a-share FFO guidance increase, supported by $0.80 from One Vanderbilt accounting change
- 2 Vanguard ETFs Built to Thrive as Big Tech Loses Its Market Grip
- Galaxy Digital prices $3.5B senior secured notes offering
- Australia's private sector activity accelerates in July as services & factory orders rebound
- Shares skid in Asia in sell-off of AI-related shares as Brent oil tops $100 per barrel
